Table 1.

Patient characteristics and clinical outcomes for vitrified/warmed embryo transfers

	HSA	rHA	P-value
No. of patients	831	665
Patient age (range)	34.8 ± 0.1 (22–44)	35.4 ± 0.2 (23–45)	.005
BMI (range)	20.6 ± 0.1 (14.4–32.5)	20.8 ± 0.1 (15.1–36.7)	.109
Patients undergoing their first or second IVF/ICSI treatment cycle (%)	735 (88.5)	604 (90.8)	.149
Cause of infertility
Male factor	326 (39.2)	264 (39.7)	.873
Female factor	142 (17.1)	102 (15.3)	.398
Combined and other factor	363 (43.7)	299 (45.0)	.638
No. of warmed cycles	1,163	898
No. of embryos warmed	1,274	963
No. of surviving embryos (%)	1,258 (98.7)	952 (98.9)	.848
No. of ETs	1,159	897
No. of embryos transferred	1,250	951
Mean no. of embryos transferred	1.08 ± 0.01	1.06 ± 0.01	.108
No. of implantations (%)	621 (49.7)	521 (54.8)	.018
No. of clinical pregnancies (%/ET)	597 (51.5)	502 (56.0)	.045
No. of live deliveries (%/pregnancy)	431 (72.2)	363 (72.3)	>.999
No. of miscarriages (%/pregnancy)	158 (26.5)	131 (26.1)	.945
No. of stillbirths (%/pregnancy)	2 (0.3)	2 (0.4)	>.999
No. of patients lost to follow up (%/pregnancy)	6 (1.0)	6 (1.2)	.779

Values are expressed as mean ± SEM. The vitrification/warming solutions contained either HSA (HSA group) or rHA (rHA group)